Bactiguard, a Swedish medical device company, and Zimmer Biomet have agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments.
The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), sports medicine, craniomaxillofacial and thoracic applications. It includes license and development fees of USD 1.5 million payable in 2022, additional contingent milestone payments of USD 7.5 million based on U.S. regulatory clearance for different product categories, and royalties on net sales following commercialization.
